Newbury Pharmaceuticals Q4: Reaping the rewards - Redeye

Redeye provides a research update following the Q4 report recently published by Newbury. Following continued progress in portfolio expansion, regulatory approvals and product launches, the company managed to achieve impressive sales figures for the quarter. However, as we believe that the performance of individual quarters are quite volatile in Newbury’s current state and expected strong sales figures given the previously postponed orders, we do not make any drastic changes to our estimates. We reiterate our base case valuation of SEK8.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045464/newbury-pharmaceuticals-q4-reaping-the-rewards?utm_source=finwire&utm_medium=RSS